Intellipharmaceutics International Inc. (IPCI)

[grill4thrills]

True, but the current tech behind Rexista w/ nPODDDS addresses the immediate release need, which will disrupt the current market dynamic… As described on pg. 19 of their March investor presentation, nPODDDS is described as: “Drug release provides a defined Point of Divergence (POD) in the initial loading dose provides a quick onset of action, followed by a shift in the drug release rate to a controlled release or sustained action.” They have articulated this in more detail in presentations/interviews in the past.

Users need quick acting medication to relieve pain, making IR important, but ER is great for covering pain throughout the day/night. The ideal product would have both, with ADF properties... such as Rexista (all dependent on if the FDA agrees to the claims made by IPCI regarding the product of course).